Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
Nat Med
    September 2021
  1. APOSTOLIDIS SA, Kakara M, Painter MM, Goel RR, et al
    Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
    Nat Med. 2021 Sep 14. pii: 10.1038/s41591-021-01507.
    >> Share

  2. DAGAN N, Barda N, Biron-Shental T, Makov-Assif M, et al
    Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
    Nat Med. 2021 Sep 7. pii: 10.1038/s41591-021-01490.
    >> Share

  3. SAVULESCU J, Pugh J, Wilkinson D
    Balancing incentives and disincentives for vaccination in a pandemic.
    Nat Med. 2021 Sep 6. pii: 10.1038/s41591-021-01466.
    >> Share

  4. ONEKO M, Steinhardt LC, Yego R, Wiegand RE, et al
    Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial.
    Nat Med. 2021;27:1636-1645.
    >> Share

  5. KOUP RA, Donis RO, Gilbert PB, Li AW, et al
    A government-led effort to identify correlates of protection for COVID-19 vaccines.
    Nat Med. 2021;27:1493-1494.
    >> Share

    August 2021
  6. CHAGLA Z, Pai M
    COVID-19 boosters in rich nations will delay vaccines for all.
    Nat Med. 2021 Aug 31. pii: 10.1038/s41591-021-01494.
    >> Share

    July 2021
  7. MEDEIROS-RIBEIRO AC, Aikawa NE, Saad CGS, Yuki EFN, et al
    Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
    Nat Med. 2021 Jul 30. pii: 10.1038/s41591-021-01469.
    >> Share

  8. DEMING ME, Lyke KE
    A 'mix and match' approach to SARS-CoV-2 vaccination.
    Nat Med. 2021 Jul 26. pii: 10.1038/s41591-021-01463.
    >> Share

  9. SCHMIDT T, Klemis V, Schub D, Mihm J, et al
    Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination.
    Nat Med. 2021 Jul 26. pii: 10.1038/s41591-021-01464.
    >> Share

  10. MACHINGAIDZE S, Wiysonge CS
    Understanding COVID-19 vaccine hesitancy.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01459.
    >> Share

  11. SOLIS ARCE JS, Warren SS, Meriggi NF, Scacco A, et al
    COVID-19 vaccine acceptance and hesitancy in low- and middle-income countries.
    Nat Med. 2021 Jul 16. pii: 10.1038/s41591-021-01454.
    >> Share

  12. O'LEARY K
    Another COVID-19 vaccine to boost rollout.
    Nat Med. 2021 Jul 15. pii: 10.1038/d41591-021-00045.
    >> Share

  13. BARROS-MARTINS J, Hammerschmidt SI, Cossmann A, Odak I, et al
    Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination.
    Nat Med. 2021 Jul 14. pii: 10.1038/s41591-021-01449.
    >> Share

  14. LOUBET P, Wittkop L, Tartour E, Parfait B, et al
    A French cohort for assessing COVID-19 vaccine responses in specific populations.
    Nat Med. 2021 Jul 12. pii: 10.1038/s41591-021-01435.
    >> Share

  15. CHEMAITELLY H, Yassine HM, Benslimane FM, Al Khatib HA, et al
    mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.
    Nat Med. 2021 Jul 9. pii: 10.1038/s41591-021-01446.
    >> Share

    A correlate of protection for SARS-CoV-2 vaccines is urgently needed.
    Nat Med. 2021 Jul 8. pii: 10.1038/s41591-021-01432.
    >> Share

  17. COWLING BJ, Lim WW, Cobey S
    Fractionation of COVID-19 vaccine doses could extend limited supplies and reduce mortality.
    Nat Med. 2021 Jul 5. pii: 10.1038/s41591-021-01440.
    >> Share

  18. BARBERIA LG, Costa SF, Sabino EC
    Brazil needs a coordinated and cooperative approach to tackle COVID-19.
    Nat Med. 2021;27:1133-1134.
    >> Share

  19. ALOBO M
    Strengthened health systems are needed to tackle COVID-19 in Africa.
    Nat Med. 2021;27:1126-1127.
    >> Share

  20. SINGH J, Rahman SA, Ehtesham NZ, Hira S, et al
    SARS-CoV-2 variants of concern are emerging in India.
    Nat Med. 2021;27:1131-1133.
    >> Share

  21. KHOURY DS, Cromer D, Reynaldi A, Schlub TE, et al
    Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
    Nat Med. 2021;27:1205-1211.
    >> Share

  22. LUCAS C, Klein J, Sundaram ME, Liu F, et al
    Delayed production of neutralizing antibodies correlates with fatal COVID-19.
    Nat Med. 2021;27:1178-1186.
    >> Share

    June 2021
  23. O'LEARY K
    Building a pandemic-proof vaccine.
    Nat Med. 2021 Jun 28. pii: 10.1038/d41591-021-00042.
    >> Share

  24. SALJE H, Alera MT, Chua MN, Hunsawong T, et al
    Evaluation of the extended efficacy of the Dengvaxia vaccine against symptomatic and subclinical dengue infection.
    Nat Med. 2021 Jun 24. pii: 10.1038/s41591-021-01392.
    >> Share

  25. KUSTIN T, Harel N, Finkel U, Perchik S, et al
    Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals.
    Nat Med. 2021 Jun 14. pii: 10.1038/s41591-021-01413.
    >> Share

  26. MILMAN O, Yelin I, Aharony N, Katz R, et al
    Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals.
    Nat Med. 2021 Jun 10. pii: 10.1038/s41591-021-01407.
    >> Share

  27. PRITCHARD E, Matthews PC, Stoesser N, Eyre DW, et al
    Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01410.
    >> Share

  28. PISHKO AM, Bussel JB, Cines DB
    COVID-19 vaccination and immune thrombocytopenia.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01419.
    >> Share

  29. SIMPSON CR, Shi T, Vasileiou E, Katikireddi SV, et al
    First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland.
    Nat Med. 2021 Jun 9. pii: 10.1038/s41591-021-01408.
    >> Share

  30. ROSSMAN H, Shilo S, Meir T, Gorfine M, et al
    COVID-19 dynamics after a national immunization program in Israel.
    Nat Med. 2021;27:1055-1061.
    >> Share

  31. To curb COVID-19, global health must go local.
    Nat Med. 2021;27:929.
    >> Share

    May 2021
  32. MAY M
    After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases.
    Nat Med. 2021 May 31. pii: 10.1038/s41591-021-01393.
    >> Share

  33. AU L, Fendler A, Shepherd STC, Rzeniewicz K, et al
    Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2.
    Nat Med. 2021 May 26. pii: 10.1038/s41591-021-01387.
    >> Share

  34. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2021 May 21. pii: 10.1038/s41591-021-01363.
    >> Share

  35. SCHMIDT H, Weintraub R, Williams MA, Miller K, et al
    Equitable allocation of COVID-19 vaccines in the United States.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01379.
    >> Share

  36. WARD BJ, Gobeil P, Seguin A, Atkins J, et al
    Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
    Nat Med. 2021 May 18. pii: 10.1038/s41591-021-01370.
    >> Share

  37. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2021 May 6. pii: 10.1038/s41591-021-01372.
    >> Share

  38. SINGH JA, Kochhar S, Wolff J
    Author Correction: Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 May 4. pii: 10.1038/s41591-021-01360.
    >> Share

  39. ANDREANO E, Rappuoli R
    SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies.
    Nat Med. 2021;27:759-761.
    >> Share

  40. OTU A, Agogo E, Ebenso B
    Africa needs more genome sequencing to tackle new variants of SARS-CoV-2.
    Nat Med. 2021;27:744-745.
    >> Share

    April 2021

  41. COVID-19 vaccine and blood clotting.
    Nat Med. 2021 Apr 29. pii: 10.1038/d41591-021-00025.
    >> Share

  42. DAL-RE R, Orenstein W, Caplan AL
    Being fair to participants in placebo-controlled COVID-19 vaccine trials.
    Nat Med. 2021 Apr 26. pii: 10.1038/s41591-021-01338.
    >> Share

  43. LI J, Hui A, Zhang X, Yang Y, et al
    Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.
    Nat Med. 2021 Apr 22. pii: 10.1038/s41591-021-01330.
    >> Share

  44. ZARD M, Lau LS, Bowser DM, Fouad FM, et al
    Leave no one behind: ensuring access to COVID-19 vaccines for refugee and displaced populations.
    Nat Med. 2021 Apr 19. pii: 10.1038/s41591-021-01328.
    >> Share

  45. GIORDANO G, Colaneri M, Di Filippo A, Blanchini F, et al
    Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy.
    Nat Med. 2021 Apr 16. pii: 10.1038/s41591-021-01334.
    >> Share

    The need for a new strategy for Ebola vaccination.
    Nat Med. 2021 Apr 5. pii: 10.1038/s41591-021-01313.
    >> Share

  47. EBINGER JE, Fert-Bober J, Printsev I, Wu M, et al
    Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
    Nat Med. 2021 Apr 1. pii: 10.1038/s41591-021-01325.
    >> Share

  48. EXCLER JL, Saville M, Berkley S, Kim JH, et al
    Vaccine development for emerging infectious diseases.
    Nat Med. 2021;27:591-600.
    >> Share

  49. CHEN RE, Zhang X, Case JB, Winkler ES, et al
    Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
    Nat Med. 2021;27:717-726.
    >> Share

  50. WIBMER CK, Ayres F, Hermanus T, Madzivhandila M, et al
    SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
    Nat Med. 2021;27:622-625.
    >> Share

  51. BURIONI R, Topol EJ
    Assessing the human immune response to SARS-CoV-2 variants.
    Nat Med. 2021;27:571-572.
    >> Share

  52. KINGANDA-LUSAMAKI E, Black A, Mukadi DB, Hadfield J, et al
    Integration of genomic sequencing into the response to the Ebola virus outbreak in Nord Kivu, Democratic Republic of the Congo.
    Nat Med. 2021;27:710-716.
    >> Share

    March 2021
  53. CLARKE PM, Roope LSJ, Loewen PJ, Bonnefon JF, et al
    Public opinion on global rollout of COVID-19 vaccines.
    Nat Med. 2021 Mar 30. pii: 10.1038/s41591-021-01322.
    >> Share

  54. LEVINE-TIEFENBRUN M, Yelin I, Katz R, Herzel E, et al
    Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
    Nat Med. 2021 Mar 29. pii: 10.1038/s41591-021-01316.
    >> Share

  55. PLANAS D, Bruel T, Grzelak L, Guivel-Benhassine F, et al
    Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
    Nat Med. 2021 Mar 26. pii: 10.1038/s41591-021-01318.
    >> Share

    Vaccines reduce childhood mortality.
    Nat Med. 2021 Mar 18. pii: 10.1038/d41591-021-00014.
    >> Share

  57. SINGH JA, Kochhar S, Wolff J
    Placebo use and unblinding in COVID-19 vaccine trials: recommendations of a WHO Expert Working Group.
    Nat Med. 2021 Mar 16. pii: 10.1038/s41591-021-01299.
    >> Share

  58. EKSTROM AM, Berggren C, Tomson G, Gostin LO, et al
    The battle for COVID-19 vaccines highlights the need for a new global governance mechanism.
    Nat Med. 2021 Mar 11. pii: 10.1038/s41591-021-01288.
    >> Share

  59. MARHOLD K, Fell J
    Electronic vaccination certificates: avoiding a repeat of the contact-tracing 'format wars'.
    Nat Med. 2021 Mar 4. pii: 10.1038/s41591-021-01286.
    >> Share

  60. DURRHEIM DN, Andrus JK, Tabassum S, Bashour H, et al
    A dangerous measles future looms beyond the COVID-19 pandemic.
    Nat Med. 2021;27:360-361.
    >> Share

  61. AHMED I
    Dismantling the anti-vaxx industry.
    Nat Med. 2021;27:366.
    >> Share

    February 2021
  62. VAN DER VELDT AAM, Oosting SF, Dingemans AC, Fehrmann RSN, et al
    COVID-19 vaccination: the VOICE for patients with cancer.
    Nat Med. 2021 Feb 15. pii: 10.1038/s41591-021-01240.
    >> Share

  63. XIE X, Liu Y, Liu J, Zhang X, et al
    Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
    Nat Med. 2021 Feb 8. pii: 10.1038/s41591-021-01270.
    >> Share

  64. COVID-19 vaccines: acting on the evidence.
    Nat Med. 2021 Feb 4. pii: 10.1038/s41591-021-01261.
    >> Share

  65. STOWER H
    A functioning vaccine in mouse models of multiple sclerosis.
    Nat Med. 2021 Feb 1. pii: 10.1038/d41591-021-00006.
    >> Share

    January 2021
  66. HU Z, Leet DE, Allesoe RL, Oliveira G, et al
    Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma.
    Nat Med. 2021 Jan 21. pii: 10.1038/s41591-020-01206.
    >> Share

  67. KIM JH, Marks F, Clemens JD
    Looking beyond COVID-19 vaccine phase 3 trials.
    Nat Med. 2021 Jan 19. pii: 10.1038/s41591-021-01230.
    >> Share

  68. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    Author Correction: A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2021 Jan 11. pii: 10.1038/s41591-020-01226.
    >> Share

    Women and children last? Shaking up exclusion criteria for vaccine trials.
    Nat Med. 2021;27:8.
    >> Share

  70. WAGAR LE, Salahudeen A, Constantz CM, Wendel BS, et al
    Modeling human adaptive immune responses with tonsil organoids.
    Nat Med. 2021;27:125-135.
    >> Share

  71. BURTON DR, Topol EJ
    Toward superhuman SARS-CoV-2 immunity?
    Nat Med. 2021;27:5-6.
    >> Share

    December 2020
  72. EWER KJ, Barrett JR, Belij-Rammerstorfer S, Sharpe H, et al
    T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01194.
    >> Share

  73. BARRETT JR, Belij-Rammerstorfer S, Dold C, Ewer KJ, et al
    Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
    Nat Med. 2020 Dec 17. pii: 10.1038/s41591-020-01179.
    >> Share

  74. NACHBAGAUER R, Feser J, Naficy A, Bernstein DI, et al
    A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.
    Nat Med. 2020 Dec 7. pii: 10.1038/s41591-020-1118.
    >> Share

    Vaccines in the fast lane.
    Nat Med. 2020;26:1807.
    >> Share

    November 2020
  76. GALLAGHER ME, Sieben AJ, Nelson KN, Kraay ANM, et al
    Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates.
    Nat Med. 2020 Nov 23. pii: 10.1038/s41591-020-01172.
    >> Share

    October 2020
  77. LAZARUS JV, Ratzan SC, Palayew A, Gostin LO, et al
    A global survey of potential acceptance of a COVID-19 vaccine.
    Nat Med. 2020 Oct 20. pii: 10.1038/s41591-020-1124.
    >> Share

  78. Scientists, keep an open line of communication with the public.
    Nat Med. 2020;26:1495.
    >> Share

    September 2020
  79. STOWER H
    Developing COVID-19 vaccines.
    Nat Med. 2020 Sep 10. pii: 10.1038/d41591-020-00029.
    >> Share

  80. TOSTANOSKI LH, Wegmann F, Martinot AJ, Loos C, et al
    Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters.
    Nat Med. 2020 Sep 3. pii: 10.1038/s41591-020-1070.
    >> Share

    August 2020
    Vaccines targeting SARS-CoV-2 tested in humans.
    Nat Med. 2020 Aug 24. pii: 10.1038/s41591-020-1048.
    >> Share

  82. STOWER H
    Seeds of hope in COVID-19 vaccine preliminary data.
    Nat Med. 2020;26:1170.
    >> Share

  83. PARK JK, Xiao Y, Ramuta MD, Rosas LA, et al
    Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.
    Nat Med. 2020;26:1240-1246.
    >> Share

    July 2020
  84. ARNOLD C
    How computational immunology changed the face of COVID-19 vaccine development.
    Nat Med. 2020 Jul 15. pii: 10.1038/d41591-020-00027.
    >> Share

    June 2020
  85. STOWER H
    Vaccination combats antimicrobial resistance.
    Nat Med. 2020 Jun 11. pii: 10.1038/s41591-020-0957.
    >> Share

  86. 'T HOEN E
    Protect against market exclusivity in the fight against COVID-19.
    Nat Med. 2020;26:813.
    >> Share

    May 2020
  87. ARUNACHALAM PS, Charles TP, Joag V, Bollimpelli VS, et al
    T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.
    Nat Med. 2020 May 11. pii: 10.1038/s41591-020-0858.
    >> Share

    April 2020
  88. MOTHE B, Brander C
    Small steps forward for HIV vaccine development.
    Nat Med. 2020 Apr 2. pii: 10.1038/s41591-020-0837.
    >> Share

    March 2020
  89. COLBY DJ, Sarnecki M, Barouch DH, Tipsuk S, et al
    Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
    Nat Med. 2020 Mar 23. pii: 10.1038/s41591-020-0774.
    >> Share

  90. TADROS AR, Romanyuk A, Miller IC, Santiago A, et al
    STAR particles for enhanced topical drug and vaccine delivery.
    Nat Med. 2020;26:341-347.
    >> Share

    February 2020
  91. KOTLIAROV Y, Sparks R, Martins AJ, Mule MP, et al
    Broad immune activation underlies shared set point signatures for vaccine responsiveness in healthy individuals and disease activity in patients with lupus.
    Nat Med. 2020 Feb 24. pii: 10.1038/s41591-020-0769.
    >> Share

  92. LANGENBERG MCC, Hoogerwerf MA, Koopman JPR, Janse JJ, et al
    A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics.
    Nat Med. 2020 Feb 17. pii: 10.1038/s41591-020-0759.
    >> Share

  93. DUSSUPT V, Sankhala RS, Gromowski GD, Donofrio G, et al
    Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Nat Med. 2020 Feb 3. pii: 10.1038/s41591-019-0746.
    >> Share

  94. DORE GJ, Martinello M, Alavi M, Grebely J, et al
    Global elimination of hepatitis C virus by 2030: why not?
    Nat Med. 2020;26:157-160.
    >> Share

    January 2020
  95. STOWER H
    A conjugate vaccine for typhoid.
    Nat Med. 2020;26:21.
    >> Share

    October 2019
  96. EHRHARDT SA, Zehner M, Krahling V, Cohen-Dvashi H, et al
    Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0602.
    >> Share

  97. STOWER H
    Supporting HPV vaccination.
    Nat Med. 2019 Oct 7. pii: 10.1038/s41591-019-0618.
    >> Share

    A glimpse into immune responses evolving against Ebola virus.
    Nat Med. 2019;25:1470-1471.
    >> Share

    August 2019
  99. CHAN KR, Gan ES, Chan CYY, Liang C, et al
    Metabolic perturbations and cellular stress underpin susceptibility to symptomatic live-attenuated yellow fever infection.
    Nat Med. 2019;25:1218-1224.
    >> Share

  100. PEEPLES L
    Rethinking herd immunity.
    Nat Med. 2019;25:1178-1180.
    >> Share

    July 2019

  101. Time to vaccinate against hesitancy.
    Nat Med. 2019 Jul 3. pii: 10.1038/s41591-019-0524.
    >> Share

    May 2019

  102. HIV vaccines go to trial.
    Nat Med. 2019;25:703.
    >> Share

    April 2019
  103. HAMMERICH L, Marron TU, Upadhyay R, Svensson-Arvelund J, et al
    Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.
    Nat Med. 2019 Apr 8. pii: 10.1038/s41591-019-0410.
    >> Share

    January 2019
  104. YAMAYOSHI S, Kawaoka Y
    Current and future influenza vaccines.
    Nat Med. 2019 Jan 28. pii: 10.1038/s41591-018-0340.
    >> Share

  105. DIJKMAN K, Sombroek CC, Vervenne RAW, Hofman SO, et al
    Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques.
    Nat Med. 2019 Jan 21. pii: 10.1038/s41591-018-0319.
    >> Share

    November 2018
  106. FARRELL A
    A vaccine for tuberculosis.
    Nat Med. 2018;24:1637.
    >> Share

    September 2018
  107. ACKERMAN ME, Das J, Pittala S, Broge T, et al
    Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV.
    Nat Med. 2018 Sep 3. pii: 10.1038/s41591-018-0161.
    >> Share

    August 2018
  108. OKOYE AA, Hansen SG, Vaidya M, Fukazawa Y, et al
    Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.
    Nat Med. 2018 Aug 6. pii: 10.1038/s41591-018-0130.
    >> Share

    June 2018
  109. XU K, Acharya P, Kong R, Cheng C, et al
    Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
    Nat Med. 2018;24:857-867.
    >> Share

    May 2018
  110. VACCARI M, Fourati S, Gordon SN, Brown DR, et al
    HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a decreased risk of SIVmac251 acquisition.
    Nat Med. 2018 May 21. pii: 10.1038/s41591-018-0025.
    >> Share

    April 2018

  111. A checkup for the flu vaccine.
    Nat Med. 2018;24:375.
    >> Share

  112. DRAPER SJ, Higgins MK
    A new site of attack for a malaria vaccine.
    Nat Med. 2018;24:382-383.
    >> Share

    March 2018
    Going live: How microRNAs might bring living vaccines back into the fold.
    Nat Med. 2018;24:248-250.
    >> Share

    February 2018
    A shot at contraception: In India, a nonagenarian renews testing of a birth control vaccine.
    Nat Med. 2018;24:118-120.
    >> Share

  115. CARPENTER SM, Behar SM
    A new vaccine for tuberculosis in rhesus macaques.
    Nat Med. 2018;24:124-126.
    >> Share

    January 2018
  116. HANSEN SG, Zak DE, Xu G, Ford JC, et al
    Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine.
    Nat Med. 2018 Jan 15. pii: nm.4473. doi: 10.1038/nm.4473.
    >> Share

  117. JANSEN KU, Knirsch C, Anderson AS
    The role of vaccines in preventing bacterial antimicrobial resistance.
    Nat Med. 2018;24:10-19.
    >> Share

    November 2017
  118. ARNOLD C
    Stalking new vaccines: Methods that target the stems of viral proteins could put universal vaccines within reach.
    Nat Med. 2017;23:1248-1250.
    >> Share

    July 2016
  119. MODJARRAD K, Moorthy VS, Ben Embarek P, Van Kerkhove M, et al
    A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation.
    Nat Med. 2016;22:701-5.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016